Home / Inspections / 1316756

FDA Inspection 1316756 — Frontida BioPharm Inc

Frontida BioPharm Inc — FEI 2523348

The FDA completed an inspection of Frontida BioPharm Inc on April 2, 2026 in Philadelphia, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
April 2, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Philadelphia, PA (United States)

Facility

Other inspections at this facility

  • 1279864 (NAI Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1226606 (VAI Thu Dec 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1097023 (VAI Fri Jul 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1007832 (VAI Fri Mar 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 936055 (OAI Fri Jul 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time))

Recent compliance actions

FDA data resources